Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ, Zhao XY, Huang XJ.
Front Immunol. 2018 Dec 21;9:3041. doi: 10.3389/fimmu.2018.03041. eCollection 2018.
Graft-versus-leukemia reactions after bone marrow transplantation.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, et al.
Blood. 1990 Feb 1;75(3):555-62.
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, Cazzaniga G, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A.
J Clin Invest. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473.
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.
Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, Wang M, Chen H, Chen YH, Wang FR, Wei-Han, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ.
Cell Mol Immunol. 2021 May;18(5):1172-1185. doi: 10.1038/s41423-020-00597-1. Epub 2021 Jan 6.
Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease.
Litvinova E, Maury S, Boyer O, Bruel S, Benard L, Boisserie G, Klatzmann D, Cohen JL.
Blood. 2002 Sep 15;100(6):2020-5. doi: 10.1182/blood-2002-01-0161.
Kras-Deficient T Cells Attenuate Graft-versus-Host Disease but Retain Graft-versus-Leukemia Activity.
Luo L, Chen Y, Chen X, Zheng Y, Zhou V, Yu M, Burns R, Zhu W, Fu G, Felix JC, Hartley C, Damnernsawad A, Zhang J, Wen R, Drobyski WR, Gao C, Wang D.
J Immunol. 2020 Dec 15;205(12):3480-3490. doi: 10.4049/jimmunol.2000006. Epub 2020 Nov 6.
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH.
N Engl J Med. 1994 Jan 13;330(2):100-6. doi: 10.1056/NEJM199401133300204.
MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
Wu Y, Heinrichs J, Bastian D, Fu J, Nguyen H, Schutt S, Liu Y, Jin J, Liu C, Li QJ, Xia C, Yu XZ.
Blood. 2015 Sep 10;126(11):1314-23. doi: 10.1182/blood-2015-02-627356. Epub 2015 Jul 2.
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S, Deng B, Yin Z, Lin Y, An L, Liu D, Pan J, Yu X, Chen B, Wu T, Chang AH, Tong C.
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
